title: Bevacizumab treatment for acute branch retinal vein occlusion accompanied by subretinal hemorrhage.
abstract: OBJECTIVE
  The purpose of this study was to compare the efficacy of intravitreal bevacizumab (IVB) in the treatment of acute (<3 months [mo]. duration) macular edema (ME), with or without subretinal hemorrhage (SRH), resulting from branch retinal vein occlusion (BRVO).
  
  
  METHODS
  We conducted a retrospective review of 33 consecutive patients (n = 33 eyes) with ME caused by acute BRVO. All patients received an injection of IVB at baseline examination. All patients were followed monthly, with administration of additional IVB injections if there was persistent or recurrent ME. Specific patterns of ME were investigated using spectral-domain optical coherence tomography (SD-OCT).
  
  
  RESULTS
  SD-OCT revealed serous retinal detachments in the fovea of 15 eyes, 10 of which had accompanying foveal SRH. Based on initial detection of foveal SRH, patients were divided into SRH-negative (n = 23 eyes) or SRH-positive (n = 10 eyes) groups. Initial best-corrected visual acuity (BCVA) did not differ between the two groups. In the SRH-negative group, both BCVA and central macular thickness (CMT) improved significantly after IVB injections (mean, 2.3 injections) at the 6-mo. follow-up examination. In the SRH-positive group, there was no significant improvement in BCVA after IVB injections (mean, 2.0 injections), although there was a significant decrease in CMT. The final BCVA of the SRH-positive group was significantly poorer than that of the SRH-negative group (p = 0.001).
  
  
  CONCLUSIONS
  The presence of foveal SRH may be a negative predictor of IVB treatment outcomes for BRVO patients with ME.
authors.affiliation: Department of Ophthalmology, Peking University Third Hospital; Peking University Eye Center, Key Laboratory of Vision Loss and Restoration, Ministry of Education , Beijing , P.R. China.
authors.forename: Lin
authors.initials: L
authors.lastname: Zhao
authors.forename: Bingzhen
authors.initials: B
authors.lastname: Li
authors.forename: Kang
authors.initials: K
authors.lastname: Feng
authors.forename: Liang
authors.initials: L
authors.lastname: Han
authors.forename: Zhizhong
authors.initials: Z
authors.lastname: Ma
authors.forename: Yuling
authors.initials: Y
authors.lastname: Liu
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D012166:Retinal Hemorrhage / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D012170:Retinal Vein Occlusion / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D012189:Retrospective Studies; D012307:Risk Factors; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab
keywords: Bevacizumab; branch retinal vein occlusion; macular edema; optical coherence tomography; subretinal hemorrhage